骨髓间充质干细胞对肝衰竭患者生存预后的影响  

Effect of Bone Marrow Mesenchymal Stem Cell Transplantation on Survival Prognosis of Patients with Liver Failure

作　　者：张美华[1] 黄建伟[1] 温凌[1] 王巧瑜[1] 潘洁[1] 

机构地区：[1]广州市第十二人民医院消化内科,广州510620

出　　处：《实用临床医学（江西）》2015年第6期15-17,共3页Practical Clinical Medicine

摘　　要：目的探讨骨髓间充质干细胞(BMSCs)对肝衰竭患者生存预后的影响。方法将60例肝衰竭患者按随机数字表法分为观察组和对照组,每组30例。对照组给予标准内科护肝、退黄(促肝细胞生长素、复方甘草酸苷、思美泰等)等综合治疗,1个月为1个疗程。观察组在标准内科综合治疗基础上加用BMSCs移植治疗,5d为1个疗程。测定并观察2组血清中肝功能指标[谷丙转氨酶(ALT)、总胆红素(TBIL)、白蛋白(ALB)],肿瘤坏死因子-α(TNF-α)、IL-1β等细胞因子水平及凝血功能指标[凝血酶原时间(PT),部分凝血活酶时间(APTT)]的变化,对2组患者的疗效进行比较。结果观察组治疗后ALT、TBIL、PT、APTT、TNF-α及IL-1β均明显低于对照组,ALB明显高于对照组(P<0.05或P<0.01)。观察组总有效率为96.67%,对照组总有效率为73.33%,2组比较差异有统计学意义(P<0.05)。结论 BMSCs移植治疗对于肝衰竭患者的生存预后具有重要意义。ABSTRACT:Objective To study the effect of transplantation of bone marrow mesenchymal stem cells(BMSCs)on survival prognosis of patients with liver failure.Methods Sixty patients with liver failure were randomly divided into two groups,with 30 patients in each group.Patients in control group were given standard liver protection,jaundice elimination(hepatocyte growth fac-tor,compound glycyrrhizin,transmetil,etc.)and other comprehensive treatments for 1 month in each course.Patients in observation group were treated with the transplantation of BMSCs for 5 day in each course,based on the comprehensive treatment.The levels of alanine transaminase (ALT),total bilirubin(TBIL),albumin(ALB),tumor necrosis factor-α(TNF-α),interleukin-1β(IL-1β),prothrombin time(PT)and partial thromboplastin time(APTT)were measured in both groups.In addition,the curative efficacy was compared between the two groups.Results Com-pared with control group,levels of ALT,TBIL,PT,APTT,TNF-αand IL-1βdecreased and levels of ALB increased in observation group(P <0.05 orP <0.01).Furthermore,the total effective rate in observation group was higher than that in control group(96.67% vs 73.33%,P <0.05).Con-clusion The transplantation of BMSCs is of great significance for survival prognosis of patients with liver failure.

关 键 词：骨髓间充质干细胞 肝衰竭 生存预后 影响 

分 类 号：R575.3[医药卫生—消化系统]